Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17672043 | 0.93 | HDAC1 (0.42) | ROCK1ROCK2HDAC1HDAC2HDAC8 | |
| SCHEMBL17672153 | 0.93 | HDAC1 (0.42) | ROCK1ROCK2HDAC1HDAC2HDAC8 | |
| SCHEMBL17671974 | 0.93 | ROCK1 (0.44) | ROCK1ROCK2HDAC1HDAC2HDAC8 | |
| SCHEMBL17671855 | 0.93 | ROCK1 (0.44) | ROCK1ROCK2HDAC1HDAC2HDAC8 | |
| SCHEMBL16147755 | 0.91 | PPARD (0.51) | ROCK1ROCK2PPARD | |
| SCHEMBL16148800 | 0.90 | HDAC1 (0.55) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL16147649 | 0.90 | ROCK1 (0.46) | ROCK1ROCK2PPARD | |
| SCHEMBL16148197 | 0.88 | HDAC1 (0.47) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL16147383 | 0.86 | HDAC1 (0.47) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL22100277 | 0.86 | OXTR (0.48) | HDAC1HDAC2HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938234-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-04-10 | — | — | US | claimed |
| EP-2981522-A1 | PPAR AGONISTS | Salk Institute for Biological Studies (US) | 2016-02-10 | — | — | EP | claimed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | claimed |
| WO-2014165827-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-10-09 | — | — | WO | claimed |
| US-20240075025-A1 | Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-03-07 | — | — | US | disclosed |
| US-11813258-B2 | Therapy for mitochondrial fatty acid beta-oxidation and transport disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-11-14 | — | — | US | disclosed |
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210308128-A1 | Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-07 | — | — | US | disclosed |
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-11077105-B2 | Therapy for mitochondrial fatty acid beta-oxidation and transport disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| US-9938234-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016057322-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-2981522-A1 | PPAR AGONISTS | Salk Institute for Biological Studies (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014165827-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165827-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | ROCK1 4729/4885ROCK2 4792/4885HDAC1 1137/4885 |
| US-20160023991-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | ROCK1 4729/4885ROCK2 4792/4885HDAC1 1137/4885 |
| US-20240075025-A1 | Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders | HADHB, HADHA, NDUFAB1 | ROCK1 4874/4885ROCK2 4848/4885HDAC1 2389/4885 |
| US-11813258-B2 | Therapy for mitochondrial fatty acid beta-oxidation and transport disorders | HADHB, HADHA, CPT2 | ROCK1 4872/4885ROCK2 4836/4885HDAC1 2694/4885 |
| US-20210308128-A1 | Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders | HADHB, HADHA, CPT2 | ROCK1 4872/4885ROCK2 4836/4885HDAC1 2694/4885 |
| US-11077105-B2 | Therapy for mitochondrial fatty acid beta-oxidation and transport disorders | HADHB, HADHA, NDUFAB1 | ROCK1 4870/4885ROCK2 4825/4885HDAC1 2900/4885 |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | ROCK1 4790/4885ROCK2 4853/4885HDAC1 1824/4885 |
| US-11130779-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | ROCK1 4790/4885ROCK2 4853/4885HDAC1 1824/4885 |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | ROCK1 4826/4885ROCK2 4860/4885HDAC1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.